PHARMACOGENETICS OF DIABETES PREVENTION

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 噻唑烷二酮类（TZD）是一种用于治疗2型糖尿病（T2 DM）的相对较新的胰岛素增敏剂;然而，30-40%的受试者对TZD治疗无反应。我们推测PPARG 2编码基因或TZDs代谢相关基因的变异可能介导TZDs的反应。我们建议在有妊娠糖尿病史的拉丁妇女中进行一项为期三个月的开放标签吡格列酮（PIO）试验，以评估候选基因与吡格列酮反应之间的遗传关联。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Thiazolidinediones (TZD) are relatively new class of insulin-sensitizing agents used to treat type 2 diabetes mellitus (T2DM); however, 30-40% of subjects do not respond to TZD therapy. We hypothesize that variation in the genes encoding for PPARG2 or genes involved in the metabolism of TZDs may mediate response to TZDs. We propse a three month open-label piolitazone (PIO) trial in Latinas with previous gestational diabetes (GDM) to assess genetic association between candidate genes and response to pioglitazone.